TY - JOUR
T1 - Stimulant-related reductions of growth rates in the PATS
AU - Swanson, James
AU - Greenhill, Laurence
AU - Wigal, Tim
AU - Kollins, Scott
AU - Stehli, Annamarie
AU - Davies, Mark
AU - Chuang, Shirley
AU - Vitiello, Benedetto
AU - Skrobala, Anne
AU - Posner, Kelly
AU - Abikoff, Howard
AU - Oatis, Melvin
AU - McCracken, James
AU - McGough, James
AU - Riddle, Mark
AU - Ghuman, Jaswinder
AU - Cunningham, Charles
AU - Wigal, Sharon
PY - 2006/11
Y1 - 2006/11
N2 - OBJECTIVE: To investigate growth of children with attention-deficit/ hyperactivity disorder (ADHD) in the Preschool ADHD Treatment Study (PATS) before and after initiation of treatment with methylphenidate at titrated doses (average, 14.2 mg/day) administered three times daily, 7 days/week for ≈1 year. METHOD: The heights and weights of 140 children with ADHD were measured up to 29 times in the PATS protocol, starting at an average age of 4.4 years. The relationship between standard (z) scores and time on medication was examined using mixed-effect regression to estimate change in relative size (slope). RESULTS: Average relative size at baseline was significantly (p < .0001) greater than zero for z height (+0.45) and z weight (+0.78), indicating greater than expected height (by 2.04 cm) and weight (by 1.78 kg). During treatment, slopes were significantly (p < .0001) less than zero for z height (-0.304/yr) and z weight (-0.530/yr), indicating reduction of growth rates. For 95 children who remained on medication, annual growth rates were 20.3% less than expected for height (5.41 cm/yr - 6.79 cm/yr = -1.38 cm/yr) and 55.2% for weight (1.07 kg/yr - 2.39 kg/yr = -1.32 kg/yr). CONCLUSIONS: Risks of reduced growth rates should be balanced against expected benefits when preschool-age children are treated with stimulant medication. Copyright 2006
AB - OBJECTIVE: To investigate growth of children with attention-deficit/ hyperactivity disorder (ADHD) in the Preschool ADHD Treatment Study (PATS) before and after initiation of treatment with methylphenidate at titrated doses (average, 14.2 mg/day) administered three times daily, 7 days/week for ≈1 year. METHOD: The heights and weights of 140 children with ADHD were measured up to 29 times in the PATS protocol, starting at an average age of 4.4 years. The relationship between standard (z) scores and time on medication was examined using mixed-effect regression to estimate change in relative size (slope). RESULTS: Average relative size at baseline was significantly (p < .0001) greater than zero for z height (+0.45) and z weight (+0.78), indicating greater than expected height (by 2.04 cm) and weight (by 1.78 kg). During treatment, slopes were significantly (p < .0001) less than zero for z height (-0.304/yr) and z weight (-0.530/yr), indicating reduction of growth rates. For 95 children who remained on medication, annual growth rates were 20.3% less than expected for height (5.41 cm/yr - 6.79 cm/yr = -1.38 cm/yr) and 55.2% for weight (1.07 kg/yr - 2.39 kg/yr = -1.32 kg/yr). CONCLUSIONS: Risks of reduced growth rates should be balanced against expected benefits when preschool-age children are treated with stimulant medication. Copyright 2006
KW - Attention-deficit/hyperactivity disorder
KW - Growth
KW - Stimulant medication
UR - http://www.scopus.com/inward/record.url?scp=33750527984&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750527984&partnerID=8YFLogxK
U2 - 10.1097/01.chi.0000235075.25038.5a
DO - 10.1097/01.chi.0000235075.25038.5a
M3 - Article
C2 - 17023868
AN - SCOPUS:33750527984
SN - 0890-8567
VL - 45
SP - 1304
EP - 1313
JO - Journal of the American Academy of Child Psychiatry
JF - Journal of the American Academy of Child Psychiatry
IS - 11
ER -